S&P 500   3,203.11 (-0.73%)
DOW   26,705.95 (-0.61%)
QQQ   257.51 (-1.30%)
AAPL   385.13 (-1.48%)
MSFT   204.09 (-1.90%)
FB   239.39 (-0.37%)
GOOGL   1,504.68 (-0.80%)
AMZN   2,961.28 (-1.58%)
NVDA   401.90 (-1.76%)
CGC   17.87 (-1.54%)
BABA   243.31 (-2.37%)
MU   49.92 (-1.17%)
GE   7.11 (-0.42%)
TSLA   1,492.97 (-3.43%)
AMD   54.24 (-1.99%)
T   30.24 (+0.77%)
ACB   12.17 (-5.44%)
F   6.84 (+1.48%)
GILD   75.97 (-0.89%)
DIS   119.24 (-1.37%)
NFLX   517.20 (-1.16%)
BAC   24.01 (-2.40%)
BA   181.51 (-3.42%)
S&P 500   3,203.11 (-0.73%)
DOW   26,705.95 (-0.61%)
QQQ   257.51 (-1.30%)
AAPL   385.13 (-1.48%)
MSFT   204.09 (-1.90%)
FB   239.39 (-0.37%)
GOOGL   1,504.68 (-0.80%)
AMZN   2,961.28 (-1.58%)
NVDA   401.90 (-1.76%)
CGC   17.87 (-1.54%)
BABA   243.31 (-2.37%)
MU   49.92 (-1.17%)
GE   7.11 (-0.42%)
TSLA   1,492.97 (-3.43%)
AMD   54.24 (-1.99%)
T   30.24 (+0.77%)
ACB   12.17 (-5.44%)
F   6.84 (+1.48%)
GILD   75.97 (-0.89%)
DIS   119.24 (-1.37%)
NFLX   517.20 (-1.16%)
BAC   24.01 (-2.40%)
BA   181.51 (-3.42%)
S&P 500   3,203.11 (-0.73%)
DOW   26,705.95 (-0.61%)
QQQ   257.51 (-1.30%)
AAPL   385.13 (-1.48%)
MSFT   204.09 (-1.90%)
FB   239.39 (-0.37%)
GOOGL   1,504.68 (-0.80%)
AMZN   2,961.28 (-1.58%)
NVDA   401.90 (-1.76%)
CGC   17.87 (-1.54%)
BABA   243.31 (-2.37%)
MU   49.92 (-1.17%)
GE   7.11 (-0.42%)
TSLA   1,492.97 (-3.43%)
AMD   54.24 (-1.99%)
T   30.24 (+0.77%)
ACB   12.17 (-5.44%)
F   6.84 (+1.48%)
GILD   75.97 (-0.89%)
DIS   119.24 (-1.37%)
NFLX   517.20 (-1.16%)
BAC   24.01 (-2.40%)
BA   181.51 (-3.42%)
S&P 500   3,203.11 (-0.73%)
DOW   26,705.95 (-0.61%)
QQQ   257.51 (-1.30%)
AAPL   385.13 (-1.48%)
MSFT   204.09 (-1.90%)
FB   239.39 (-0.37%)
GOOGL   1,504.68 (-0.80%)
AMZN   2,961.28 (-1.58%)
NVDA   401.90 (-1.76%)
CGC   17.87 (-1.54%)
BABA   243.31 (-2.37%)
MU   49.92 (-1.17%)
GE   7.11 (-0.42%)
TSLA   1,492.97 (-3.43%)
AMD   54.24 (-1.99%)
T   30.24 (+0.77%)
ACB   12.17 (-5.44%)
F   6.84 (+1.48%)
GILD   75.97 (-0.89%)
DIS   119.24 (-1.37%)
NFLX   517.20 (-1.16%)
BAC   24.01 (-2.40%)
BA   181.51 (-3.42%)
Log in

NASDAQ:LMNXLuminex Stock Price, Forecast & News

$34.79
-1.23 (-3.41 %)
(As of 07/16/2020 12:25 PM ET)
Add
Compare
Today's Range
$34.79
Now: $34.79
$36.53
50-Day Range
$28.50
MA: $30.80
$33.36
52-Week Range
$17.34
Now: $34.79
$40.21
Volume14,340 shs
Average Volume653,492 shs
Market Capitalization$1.59 billion
P/E RatioN/A
Dividend Yield1.07%
Beta0.67
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group A strep assays, ARIES bordetella assays, ARIES GBS assay, and ARIES C. difficile assays; and VERIGENE test cartridges, as well as operates as an original equipment manufacturer of custom reagents and instrumentation. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.
Read More
Luminex logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:LMNX
CUSIP55027E10
Phone512-219-8020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$334.64 million
Cash Flow$0.44 per share
Book Value$10.32 per share

Profitability

Net Income$-3,840,000.00

Miscellaneous

Employees1,247
Market Cap$1.59 billion
Next Earnings Date7/29/2020 (Estimated)
OptionableOptionable

Receive LMNX News and Ratings via Email

Sign-up to receive the latest news and ratings for LMNX and its competitors with MarketBeat's FREE daily newsletter.

Luminex (NASDAQ:LMNX) Frequently Asked Questions

How has Luminex's stock been impacted by COVID-19 (Coronavirus)?

Luminex's stock was trading at $27.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LMNX shares have increased by 29.4% and is now trading at $35.08. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Luminex?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 1 sell rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Luminex.

When is Luminex's next earnings date?

Luminex is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Luminex.

How were Luminex's earnings last quarter?

Luminex Co. (NASDAQ:LMNX) released its quarterly earnings results on Monday, May, 4th. The medical instruments supplier reported $0.01 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.01) by $0.02. The medical instruments supplier had revenue of $90.40 million for the quarter, compared to analysts' expectations of $82.30 million. Luminex had a negative net margin of 1.81% and a negative return on equity of 1.25%. Luminex's revenue for the quarter was up 9.7% on a year-over-year basis. During the same period last year, the firm posted $0.07 earnings per share. View Luminex's earnings history.

How often does Luminex pay dividends? What is the dividend yield for Luminex?

Luminex announced a quarterly dividend on Tuesday, May 26th. Investors of record on Thursday, June 18th will be given a dividend of $0.09 per share on Thursday, July 9th. This represents a $0.36 annualized dividend and a dividend yield of 1.03%. The ex-dividend date is Wednesday, June 17th. View Luminex's dividend history.

What guidance has Luminex issued on next quarter's earnings?

Luminex issued an update on its second quarter 2020 Pre-Market earnings guidance on Wednesday, July, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $109-110 million, compared to the consensus revenue estimate of $106.25 million.

What price target have analysts set for LMNX?

2 equities research analysts have issued 12 month target prices for Luminex's shares. Their forecasts range from $21.00 to $32.00. On average, they anticipate Luminex's share price to reach $26.50 in the next twelve months. This suggests that the stock has a possible downside of 24.5%. View analysts' price targets for Luminex.

Has Luminex been receiving favorable news coverage?

Press coverage about LMNX stock has been trending positive this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Luminex earned a coverage optimism score of 2.1 on InfoTrie's scale. They also assigned press coverage about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news about Luminex.

Are investors shorting Luminex?

Luminex saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 5,560,000 shares, an increase of 39.0% from the June 15th total of 4,000,000 shares. Based on an average daily volume of 753,600 shares, the days-to-cover ratio is currently 7.4 days. Currently, 13.1% of the shares of the company are short sold. View Luminex's Current Options Chain.

Who are some of Luminex's key competitors?

What other stocks do shareholders of Luminex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include Baidu (BIDU), NVIDIA (NVDA), Crispr Therapeutics (CRSP), Cisco Systems (CSCO), Inovio Pharmaceuticals (INO), Square (SQ), Verizon Communications (VZ), AbbVie (ABBV), American Express (AXP) and Micron Technology (MU).

Who are Luminex's key executives?

Luminex's management team includes the following people:
  • Mr. Nachum Shamir, CEO, Pres & Director (Age 65)
  • Mr. Harriss T. Currie, CFO, Sr. VP of Fin. & Treasurer (Age 57)
  • Mr. Richard W. Rew II, Sr. VP, Gen. Counsel & Corp. Sec. (Age 51)
  • Mr. Todd C. Bennett, Sr. VP of Global Sales & Customer Operations (Age 49)
  • Mr. Randall J. Myers, Sr. VP of Global Manufacturing & Quality (Age 57)

What is Luminex's stock symbol?

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Who are Luminex's major shareholders?

Luminex's stock is owned by a variety of retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.23%), Bridge City Capital LLC (0.15%) and Exchange Traded Concepts LLC (0.03%). Company insiders that own Luminex stock include Charles J Collins, G Walter Loewenbaum II, Nachum Shamir, Nancy Fairchild and Randall Myers. View institutional ownership trends for Luminex.

Which major investors are selling Luminex stock?

LMNX stock was sold by a variety of institutional investors in the last quarter, including Bridge City Capital LLC. Company insiders that have sold Luminex company stock in the last year include Charles J Collins, G Walter Loewenbaum II, Nachum Shamir, Nancy Fairchild, and Randall Myers. View insider buying and selling activity for Luminex.

Which major investors are buying Luminex stock?

LMNX stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., and Exchange Traded Concepts LLC. Company insiders that have bought Luminex stock in the last two years include G Walter Loewenbaum II, and Nachum Shamir. View insider buying and selling activity for Luminex.

How do I buy shares of Luminex?

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Luminex's stock price today?

One share of LMNX stock can currently be purchased for approximately $35.08.

How big of a company is Luminex?

Luminex has a market capitalization of $1.61 billion and generates $334.64 million in revenue each year. The medical instruments supplier earns $-3,840,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Luminex employs 1,247 workers across the globe.

What is Luminex's official website?

The official website for Luminex is www.luminexcorp.com.

How can I contact Luminex?

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]

This page was last updated on 7/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.